Effect of Avastin in Juxtafoveal Telangiectasias

Asociación para Evitar la Ceguera en México

Status and phase: Withdrawn; Phase 3

Conditions: Telangiectasis

Treatments: Drug: Bevacizumab; Procedure: Intravitreal injection of Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00406380

APEC-0024

Details and patient eligibility

About

Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

Full description

After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected visual acuity (BCVA), fluorescein angiogram (FA) and Optical Coherence Tomography (OCT)findings. We found an improvement in visual acuity and reduction of FA leakage and decrease retinal thickness in OCT.

Sex: All

Ages: 40 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion
• Patients with Idiopathic Juxtafoveal Retinal Telangiectasias

Exclusion criteria

• Diabetic Retinopathy and Diabetic Macular Edema
• Hypertensive Retinopathy
• Choroidal Neovascularization

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)